Latest Kaiser Health News Stories
Before “Medicare for All,” there was just Medicare, the federal program that provides insurance to 60 million Americans. This week, KHN’s Julie Rovner talks to Tricia Neuman of the Kaiser Family Foundation about how Medicare works and whom it serves. Then, Joanne Kenen of Politico, Paige Winfield Cunningham of The Washington Post and Kimberly Leonard of the Washington Examiner join Rovner to talk about some current Medicare issues being debated in Washington, D.C.
What changes are needed to bring home dialysis to more patients — especially older adults, the fastest-growing group of patients with serious, irreversible kidney disease? We asked nephrologists, patient advocates and dialysis company officials for their thoughts.
KHN reporter Emmarie Huetteman joined Connecticut Public Radio’s Lucy Nalpathanchil on the “Where We Live” program Tuesday to talk about the variety of options that Democratic presidential candidates are proposing for voters.
You asked about drug prices, the “Cadillac tax” on generous insurance plans and why Americans don’t know that most other countries also have combination public-private insurance systems. This week, Anna Edney of Bloomberg News, Alice Miranda Ollstein of Politico and Caitlin Owens of Axios join KHN’s Julie Rovner to answer those questions.
Politicians are throwing around a lot of terms when they talk about their health care plans: universal care, “Medicare for All,” “Medicare Buy-In.” KHN helps explain what they are talking about.
Presidential hopeful Elizabeth Warren tried to tell the story of Ady Barkan in the latest Democratic debate. He’s one of the most prominent advocates for “Medicare for All” and is spending his remaining time alive doing everything he can to make the case that all Americans need affordable health coverage.
Critics worry the delays come at a steep cost: Medicare paying for millions of unnecessary exams and patients subject to radiation for no medical benefit.
Medicare beneficiaries under observation care in the hospital can face higher costs for treatment and are not covered for nursing home care when discharged. A federal trial in Hartford, Conn., will determine whether the government’s ban on appeals involving observation care coverage is fair.
When it comes to physician-administered infusion drugs, doctors sometimes have a financial reason for their choice and patients often aren’t aware of cheaper options.
Health care was a major topic at the Democratic presidential candidate debates in Detroit on Tuesday and Wednesday, but the focus on plan minutiae may have left viewers more confused than edified. Alice Ollstein of Politico, Kimberly Leonard of the Washington Examiner and Caitlin Owens of Axios join KHN’s Julie Rovner to discuss the points made by the candidates plus a series of Trump administration health initiatives on drug prices and hospital shopping.
The Wednesday night event marked the second night in a row for Democratic presidential hopefuls to stake claims on how to fix the health care system.
The proposed rules would require hospitals to provide far more detail about the actual prices they charge insurers for patients’ care.
Capitalizing on the growing popularity of genetic testing — and fears of terminal illness — scammers are persuading seniors to hand over cheek swabs with their DNA, not knowing it may lead to identity theft and Medicare fraud.
Candidates used their varying views on how to achieve universal coverage — whether through Medicare for All or more incremental steps — as a means to differentiate themselves from the field.
Asked to choose between building on the Affordable Care Act and replacing it with a national Medicare for All plan, 55% of Democrats and Democratic-leaning independents said they would expand the existing law, according to a Kaiser Family Foundation poll released Tuesday.
The drug industry has the biggest lobbying war chest.
Even some Republicans who supported a sweeping bipartisan bill to rein in drug costs may not back it in the Senate vote.
Democrats and Republicans on the Senate Finance Committee unveiled their long-awaited proposal to try to rein in prescription drug costs, even as bipartisan leaders of the other Senate committee that oversees health announced it would not bring its drug price bill to the Senate floor until fall. Paige Winfield Cunningham of The Washington Post, Rebecca Adams of CQ Roll Call and Alice Miranda Ollstein of Politico join KHN’s Julie Rovner to discuss this, plus court actions on health issues.
Efforts to control drug prices seemed on a glide path earlier this year after gaining traction at the White House and in Congress. But prospects today look less certain and highly controversial.
Tennessee company’s Medicare billings for urine tests were examined by Kaiser Health News in 2017.